Earnings summaries and quarterly performance for Evolus.
Executive leadership at Evolus.
Board of directors at Evolus.
Research analysts who have asked questions during Evolus earnings calls.
Annabel Samimy
Stifel Financial Corp.
4 questions for EOLS
Also covers: ALT, APLS, CARA +14 more
DT
Douglas Tsao
H.C. Wainwright & Co.
3 questions for EOLS
Also covers: ALKS, APLS, ARGX +19 more
NT
Navann Ty
BNP Paribas S.A.
3 questions for EOLS
Also covers: COO, ELAN, HOLX +4 more
SB
Serge Belanger
Needham & Company
3 questions for EOLS
Also covers: AMPH, ARQT, BCRX +12 more
MY
Madhumita Yennawar
Leerink Partners
2 questions for EOLS
Also covers: MNMD
MG
Marc Goodman
Leerink Partners
2 questions for EOLS
Also covers: ACAD, ALDX, ALKS +14 more
Sam Eiber
BTIG, LLC
2 questions for EOLS
Also covers: AIRS, APYX, EMBC +6 more
UE
Uy Ear
Mizuho Securities
2 questions for EOLS
Also covers: ALKS, ARQT, NBIX +6 more
Charles
Mizuho Securities USA LLC
1 question for EOLS
Also covers: AWI, BWLP, RLMD
DT
Doug Tsao
H.C. Wainwright & Co.
1 question for EOLS
Also covers: PRAX
MF
Mikaela Franceschina
Barclays
1 question for EOLS
NT
Navann Ty Dietschi
BNP Paribas
1 question for EOLS
Also covers: COO, ELAN, GEHC +6 more
Recent press releases and 8-K filings for EOLS.
Evolus, Inc. Announces Preliminary Unaudited Q4 and Full-Year 2025 Net Revenue and 2026 Guidance
EOLS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Evolus, Inc. announced preliminary unaudited net revenue for Q4 2025 between $88.6 Million and $90.6 Million, representing 12% to 15% growth over the prior year, and for full-year 2025 between $295.5 Million and $297.5 Million, an 11% to 12% increase over 2024.
- The company reaffirmed positive non-GAAP operating income of $5 Million to $7 Million for Q4 2025 and anticipates achieving sustainable annual profitability beginning in 2026.
- For 2026, Evolus projects net revenue between $327.0 Million and $337.0 Million, representing 11% to 13% growth from preliminary 2025 results.
- The 2028 long-term financial outlook was updated, projecting total net revenue of $450 Million to $500 Million and non-GAAP operating income margins of 13% to 15%.
- As of December 31, 2025, the company reported cash and cash equivalents of $53 million.
Jan 9, 2026, 1:34 PM
Evolus Announces Preliminary Unaudited Q4 and Full-Year 2025 Net Revenue and Provides 2026 Guidance
EOLS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Evolus announced preliminary unaudited net revenue for Q4 2025 between $88.6 million and $90.6 million, representing 12% to 15% growth over the prior year, and full-year 2025 net revenue between $295.5 million and $297.5 million, an 11% to 12% increase over 2024.
- The company reaffirmed positive non-GAAP operating income of $5 million to $7 million for Q4 2025 and expects to achieve sustainable annual profitability (defined as positive non-GAAP operating income) beginning in 2026.
- Evolus provided 2026 net revenue guidance of $327.0 million to $337.0 million, which represents 11% to 13% growth from preliminary unaudited 2025 results.
- The 2028 long-term financial outlook was updated to reflect total net revenue of $450 million to $500 million and non-GAAP operating income margins of 13% to 15%.
Jan 9, 2026, 1:30 PM
Evolus Discusses Product Launches, Market Conditions, and Financial Outlook at Stifel 2025 Healthcare Conference
EOLS
Product Launch
Guidance Update
Demand Weakening
- Evolus is experiencing strong initial success with its second product, Evolysse, an HA filler, which is exceeding the launch trajectory of other recent HA products.
- The company projects achieving profitability in Q4 2025 and for the full year 2026, supported by a $25 million reduction in expenses.
- Evolus has access to $100 million in term loan capacity for business development and a $40 million revolving line of credit.
- Despite a challenging macroeconomic environment affecting the aesthetic market, particularly fillers, Evolus's Jeuveau continues to grow in the U.S., and its international business shows robust growth.
- The company plans to introduce its flagship sculpt product, Skulpt, for the mid-face in the second half of 2026, further expanding its portfolio.
Nov 11, 2025, 4:20 PM
Evolus Reports Q3 2025 Results and Reaffirms Full-Year Guidance
EOLS
Earnings
Guidance Update
Product Launch
- Evolus reported Q3 2025 net revenue of $69.0 million, representing a 13% year-over-year increase.
- The company reaffirmed its full-year 2025 total net revenue guidance of $295 million to $305 million, with Evolysse™ injectable HA gels expected to contribute 10% to 12% of this total.
- Evolus anticipates achieving non-GAAP operating income of $5 million to $7 million in Q4 2025 and projects annual profitability beginning in 2026. The Evolysse™ launch generated $5.7 million in revenue for Q3 2025 and $15.5 million year-to-date.
Nov 5, 2025, 9:30 PM
Evolus Reports Q3 2025 Results and Reiterates 2025 Outlook
EOLS
Earnings
CFO Change
Guidance Update
- Tatiana Mitchell was welcomed as the new Chief Financial Officer.
- Evolus reported global net revenue of $69 million for Q3 2025, a 13% increase over Q3 2024, driven by strong global Jeuveau demand and early contributions from Evolysse.
- The company reiterated its expectation to achieve profitability in Q4 2025 and sustainable annual profitability beginning in 2026. Full-year 2025 total net revenue guidance remains between $295 million and $305 million.
- Jeuveau continues to outperform the aesthetic market with unit volume growth year-to-date, despite overall market headwinds. The Evolysse launch has seen over 4,000 customers complete hands-on training, with the majority having purchased the product.
Nov 5, 2025, 9:30 PM
Evolus Reports Q3 2025 Results and Reiterates 2025 Guidance
EOLS
Earnings
Guidance Update
Product Launch
- Evolus reported Q3 2025 global net revenue of $69 million, a 13% increase over 2024, with Jeuveau contributing $63.2 million and Evolisse $5.7 million.
- The company achieved a non-GAAP operating loss of $3.1 million in Q3 2025, an improvement from $6.7 million in Q3 2024, and reported a gross margin of 66.5%.
- Evolus reiterated its full-year 2025 net revenue guidance of $295 million to $305 million and expects to achieve profitability in 2025, with sustainable annual profitability beginning in 2026.
- The PMA for Evolisse Sculpt was submitted to the FDA in Q3 2025, with potential approval anticipated in 2026, and a broader launch of Esteem in Europe is also planned for 2026.
- Tatiana Mitchell was welcomed as the new Chief Financial Officer.
Nov 5, 2025, 9:30 PM
Evolus Reports Q3 2025 Financial Results and Reiterates Full-Year Guidance
EOLS
Earnings
Guidance Update
Product Launch
- Evolus reported Q3 2025 global net revenue of $69 million, a 13% increase over Q3 2024, with Jeuveau contributing $63.2 million and Evolysse $5.7 million.
- The company improved its non-GAAP operating loss to $3.1 million in Q3 2025 from $6.7 million in Q3 2024, achieving a gross margin of 66.5%.
- Evolus reiterated its full-year 2025 net revenue guidance of $295 million to $305 million and expects non-GAAP operating income between $5 million and $7 million in Q4 2025, targeting sustainable annual profitability beginning in 2026.
- Strategic advancements include the submission of a PMA for Evolysse Sculpt to the FDA, with potential approval in H2 2026, and the planned broader launch of Estyme in Europe in H1 2026.
- The customer base expanded by nearly 500 new purchasing accounts in Q3, reaching over 17,000 total accounts, with 2,000 now also purchasing Evolysse.
Nov 5, 2025, 9:30 PM
Evolus Reports Third Quarter 2025 Financial Results
EOLS
Earnings
Guidance Update
- Evolus, Inc. reported total net revenue of $69.0 million for the third quarter of 2025, representing a 13% increase over Q3 2024.
- This revenue included $63.2 million from global Jeuveau® and $5.7 million from Evolysse™.
- The company expects to achieve positive non-GAAP operating income of $5 million to $7 million in Q4 2025 and is on track for sustainable annual profitability beginning in 2026.
- Evolus reaffirmed its 2025 net revenue guidance of $295 million to $305 million and non-GAAP operating expenses of $208 million to $213 million.
- Cash and cash equivalents stood at $43.5 million as of September 30, 2025.
Nov 5, 2025, 9:12 PM
Evolus Reports Third Quarter 2025 Financial Results
EOLS
Earnings
Guidance Update
Product Launch
- Evolus reported total net revenue of $69.0 million for Q3 2025, representing a 13% increase from Q3 2024, with year-to-date growth of 10%.
- Global Jeuveau® net revenue reached $63.2 million in Q3 2025, and Evolysse™ contributed $5.7 million in revenue, marking the strongest hyaluronic acid (HA) filler debut in over a decade.
- The company anticipates achieving positive non-GAAP operating income of $5 million to $7 million in Q4 2025, and remains on track for sustainable annual profitability starting in 2026.
- Evolus reaffirmed its full-year 2025 net revenue guidance of $295 million to $305 million and non-GAAP operating expenses guidance of $208 million to $213 million.
- GAAP loss from operations for Q3 2025 was $11.5 million, while non-GAAP loss from operations was $3.1 million.
Nov 5, 2025, 9:05 PM
Evolus Appoints Dr. Benjamin Eskenazi as Lead Consultant for Evolysse™ Filler Launch
EOLS
Product Launch
New Projects/Investments
- Evolus, Inc. (NASDAQ: EOLS) has named Dr. Benjamin Eskenazi as lead consultant for the national launch of its new Evolysse™ filler line.
- The FDA-approved Evolysse™ Form and Evolysse™ Smooth mark Evolus' entry into the U.S. hyaluronic acid dermal filler market, representing a major technological breakthrough.
- Dr. Eskenazi, a board-certified plastic surgeon, will leverage his expertise to support aesthetic providers, demonstrating Evolus' commitment to patient safety and education.
- The commercial launch of Evolysse™ Form and Evolysse™ Smooth is scheduled for 2025, with Evolysse™ Sculpt planned for 2026 and Evolysse™ Lips for 2027.
Sep 22, 2025, 1:03 PM
Quarterly earnings call transcripts for Evolus.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more